Guardant Health, Inc.
$22.79B- Market cap
- $21.66B
- Debt
- +$1.50B
- Cash
- −$378.20M
Capital structure 94% equity / 6% debt · EV / Revenue 23.21x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: GH stock price at premium vs ROP $161.44 current versus $37.30 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROP's multiple
Implied fair value · at GH's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GH FY 2025 (ended Dec 31, 2025) · ROP FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 23.21x
Capital structure 80% equity / 20% debt · EV / Revenue 6.33x · EV / EBITDA 15.86x
ROP carries the larger enterprise value at $49.99B against $22.79B; ROP trades on the lower EV / Revenue multiple (6.33x vs 23.21x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GUARDANT HEALTH, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ROPER TECHNOLOGIES, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-15.14x
0.50x
Net debt / EBITDA
Leverage against operating earnings
-3.04x
3.08x
Cash and equivalents
Liquid reserves on the balance sheet
$378.20M
$297.40M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEOGENOMICS INC
GH vs NEO
Fulgent Genetics, Inc.
GH vs FLGT
EXACT SCIENCES CORP
GH vs EXAS
Natera, Inc.
GH vs NTRA
HONEYWELL INTERNATIONAL INC
GH vs HON
EMERSON ELECTRIC CO
GH vs EMR
Fortive Corp
GH vs FTV
Keysight Technologies, Inc.
GH vs KEYS
METTLER TOLEDO INTERNATIONAL INC/
GH vs MTD
Vontier Corp
GH vs VNT
$1.50B
$10.01B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.